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The category of products known as dietary supplements covers a wide range  of 
products including multivitamins, herbal supplements and energy drinks. High 
performance liquid chromatography (HPLC) is a common analytical technique for 
pharmaceuticals. This study presents an HPLC method for the quantitation of several 
ingredients in dietary supplements Lentra, Prolent, and Somni-TR. 
Photodetection by polydiacetylene is another quantitative method. 
Polydiacetylenes have two optical states, a “red” and a “blue” state, and an irreversible 
transition can be triggered from the blue to the red state by the binding of an analyte to 
the polymer. The potential usefulness of PDA lies in its ability to act as both receptor and 
transducer. In this study, attempts were made to synthesize several diacetylene monomers 
which could be used in PDA thin films or vesicles. These attempts included several 
different chain lengths and functional groups.
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CHAPTER I
INTRODUCTION
Statement of Problem
Dietary or nutritional supplements are defined as a product taken orally and 
containing ingredients supposed to supplement the diet. The business of selling such 
supplements is large and growing, with sale of herbal supplements alone growing from 
$4.8 billion to $5.0 billion between 2008 and 2009.1 The FDA has placed these products 
in a gray area as a subcategory of food although many substances categorized as dietary 
supplements come in tablet or capsule form. The legal definition of a dietary 
supplement is:
A product (other than tobacco) intended to supplement the diet that bears 
or contains one or more of the following dietary ingredients: (A) a 
vitamin; (B) a mineral; (C) an herb or other botanical; (D) an amino acid; 
(E) a dietary substance for use by man to supplement the diet by 
increasing the total dietary intake; or (F) a concentrate, metabolite, 
constituent, extract, or combination of any ingredient described in clause 
(A), (B), (C), (D), or (E)2
According to the 1994 Dietary Supplement Health and Education Act, the safety 
of dietary supplements and the accuracy of advertising claims has been the responsibility 
of the manufacturer and distributor and requires no FDA approval, unlike other food 
products.3 Since the manufacturer alone is responsible for the accuracy of the product 
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label information, it is important for distributors to develop their own methods of quality 
control. 
Lentra, Prolent, and Somni-TR are supplements intended to correct 
neurotransmitter imbalance by inhibitory support. Each is a formula of ingredients chosen 
for their complementary roles in affecting  neurological systems. The following are the 
manufacturer's claims regarding their product1. Prolent and Lentra are inhibitory formulas 
for the hypothalamic-pituitary-adrenal (HPA) axis, which is the part of the 
neuroendocrine system which regulates the body's chemical reactions to stress. Over-
excitation of the HPA axis can cause anxiety  and sleeplessness, and by boosting an 
inadequate inhibitory system these symptoms can be treated. Prolent supports the 
inhibitory system in a variety of ways, including 5-hydroxytryptophan (5-HTP), a 
serotonin and melatonin precursor, and Suntheanine (a commercial preparation of L-
theanine), an agonist for gamma-aminobutyric acid (GABA), the major inhibitory 
neurotransmitter4. Lentra acts as direct support for the GABA system with taurine (a 
GABA receptor agonist), and L-theanine. Somni-TR is a sleep support formula. It utilizes 
melatonin, a hormone which is normally produced in the pineal gland and acts as part of 
the circadian cycle by causing drowsiness, and pantethine, which helps produce 
serotonin. 
It is important to the operation of these supplements that all the ingredients are 
present in the proper amounts. Five ingredients were analyzed, as follows:
1) 5-Hydroxytryptophan (5-HTP)5 can have side effects like dizziness, nausea, 
1 All manufacturer claims from person communication with Connie Shoemaker of Sanesco International.
2
fatigue,6 vomiting, and diarrhea in high doses7 and may affect decision making 
under certain conditions.8 5-HTP has also been shown to be fatally toxic to dogs 
in extremely high doses.9 
2) Melatonin, which can cause sleepiness or headaches.10 
3) L-theanine, which appears to have no ill effects at high doses in rats.11 
4) Glycine, which at high doses can cause vomiting, seizures, cyanosis, apnoea, 
oliguria, anuria and hypotension and can lead to death.12 
5) Pantethine, which has no major side effects in the literature.
Even when there are no common side effects, there can be dangerous and unforeseeable 
consequences from an accidental overdose of “natural” dietary supplements, just as for 
any drug13. Therefore making sure that these ingredients do not exceed the prescribed
amount is also an issue. 
Statement of Objective
The specific aim of this project is to create a method by which the active 
ingredients of three Sanesco products, Lentra, Prolent, and Somni-TR, can be quantified, 
ensuring that there is neither a shortage of an important ingredient nor an overabundance 
of an ingredient which could have harmful side effects. The method employed to do this 
is reverse phase high performance liquid chromatography HPLC with UV detection. In 
this form of column chromatography, the mobile phase is forced through the stationary 
phase with a pump. This chromatographic method is often preferred over the older 
gravity-based column chromatography for analytical applications because of the ability to 
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use more densely packed stationary phases, which produce superior resolution. HPLC 
with a polar stationary phase and non-polar mobile phase is classified as “normal-phase” 
while “reversed-phase” uses a non-polar stationary phase and a polar, usually aqueous 
mobile phase. Reversed-phase is more convenient for most analysis because the column 
is more stable. A mainly aqueous mobile phase can be cheaper as well as less toxic than 
the organic solvents used in normal-phase HPLC. Selectivity can be improved by 
changing the polarity of the mobile phase or adding a second mobile phase. On a 
reversed-phase system, a less polar mobile phase may cause the nonpolar analytes to 
elute faster, thus decreasing the retention time. Adding a second, less polar mobile phase 
can achieve the same effect, and retention time of the analytes can be closely controlled 
by gradually changing the proportion of less polar solvent pumped through the column 
over the course of the run. As the polarity of the mobile phase changes, less polar solutes 
migrate through the column faster. This “gradient elution” improves the peak shape and 
decreases the retention time of non-polar analytes. This allows analytes of a wide range 
of structures and polarities to be quantified over a shorter run time. In the analysis of
nutritional supplements, the analytes vary in structure as illustrated below. (Figure 1)
4
Figure 1. Structure of analytes: pantethine (1), melatonin (2), 5-HTP (3), L-theanine (4), glycine (5).
These compounds are all detectable with HPLC with UV detection, with each one 
incorporating a carboxyl, carbonyl or aromatic chromophore. This prevents the need for 
any derivatization. HPLC as a technique has good selectivity despite the similarities in 
structure between some of the analytes, although the smaller, more polar analytes such as 
glycine may come off too quickly because of low affinity with the stationary phase. A UV 
transparent buffer such as phosphate must be used as to not interfere with detection.
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CHAPTER II
REVIEW OF LITERATURE
HPLC is an efficient method of quality control for all kinds of dietary 
supplements. Most such analysis uses reverse phase chromatography with 
octadecylsilanol attached to silica gel (C18) as the stationary phase. Other alkyl groups 
can be used, with longer alkyl in general providing increased retention of the analytes. 
Normal phase is used rarely, with unmodified silica gel the most common adsorbant. The 
mobile phase is typically a mix of water and an organic solvent such as methanol or 
acetonitrile. The pH of the aqueous solvent can be important depending on the acid or 
base character of the analyte. An acid component will be ionized at higher pH, which 
decreases retention time, so a pH of 2.5-5 is preferable. A lower pH also protonates 
residual silanols on the surface of the stationary phase. This prevents ion-exchange 
reactions from occurring between the acidic silanol and a basic amine functional group 
on the solute, which can cause peak tailing. A high pH can also destroy a column over 
time by dissolving the silica in the stationary phase. The usual method of controlling the 
pH is a phosphate buffer, although an acetate buffer can be used as long as UV detection 
below 230 nm is not required.14 If the components of the mixture being analyzed are 
similar in structure and properties, then an isocratic method will suffice, but for mixtures 
such as as multivitamins with many different components a gradient is preferable15,16. A 
6
slowly increasing percentage of organic mobile phase may enable the elution of 
substances with widely varying affinity for the stationary phase. Optical ultraviolet is the 
most common detection method, but other methods include coulometric detection (a 
highly sensitive form of detection which relies on the oxidation or reduction of the 
analyte and can be used on substances lacking a chromophore) or mass spectrometry. 
The following examples are illustrative of the uses of HPLC in nutrient 
quantification. The caffeic acid derivatives in 16 commercial supplements of Echinacea 
purpurea were analyzed by HPLC in 2004, and a method of quantitation was developed 
for quantities of each derivative between 100 and 200 ng/mL.17 Two separate HPLC 
methods were tried for quantification of melatonin and soy extracts in a formulation 
intended to treat menopausal symptoms; the results were in good agreement.18 HPLC has 
been used to identify chemical fingerprints of raw plant extracts used in traditional 
medicine.19 
Ascorbic acid, more commonly known as the water-soluble vitamin C, can be 
quantitated in both human plasma and a variety of fruit juices with a C-18 column at a 
wavelength of 265nm with a linearity of 0.05-100 μg/mL.20 Vitamins B1, B6 and B12 
have been determined in fruit juice and seafood with coulometric, electrochemical and 
ultraviolet detection at 283 nm.21 Five forms of vitamin B6 have been separated 
isocratically and determined by coulometric detection22. A chromatographic method has 
been created for the simultaneous determination of seven B-complex vitamins using 
combined mass spectrometry and UV detection.23 Simultaneous detection of B2, B3, B6, 
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caffeine and taurine in energy drinks was achieved with multi-wavelength scanning, with 
UV measurement of B3 and caffeine, fluorescence measurement of B2 and B6, and 
visible wavelength measurement of derivatized taurine.24 Seven water-soluble vitamins 
have been measured in tarhana (a Turkish cereal food) by isocratic RP-HPLC with UV 
detection.25 Superheated water chromatography  using deuterium oxide has been used to 
quantify vitamins, allowing the use of NMR as a detector.26
Many of the active ingredients in these three supplements are amino acids. HPLC 
with UV-vis detection at 335 nm has been used to obtain derivitized amino acid profiles 
of proteins in vegetable oil27. 18 derivatized amino acids in olive, grapeseed, corn, 
avocado, peanut, hazelnut and soybean oil were separated with an acetonitrile/5 mM 
citrate buffer gradient within 50 minutes. HPLC has been compared to a micellar 
electrokinetic chromatography method28 for the detection of  melatonin, one of the 
ingredients of Somni-TR, and several of its metabolites. In this study, an HPLC method 
using a methanol/sodium acetate mobile phase (pH 5.1) on a C18 column and a diode 
array detector was compared to an MEKC method using phosphate buffer and SDS (pH 
3.0) and also measuring with a DAD. The HPLC method proved to have higher accuracy 
in the quantitation of 5 μg/mL melatonin, although the MEKC method was much faster 
and had a lower limit of detection.  HPLC with fluorescence detection has also been used 
to determine melatonin concentrations in bile and plasma29. 85 mM acetic acid with 0.1 
mM disodium EDTA and 14% acetonitrile (pH 4.7) was used as the mobile phase here 
and melatonin eluted at about 9 minutes. Recoveries were 89-94% with a limit of 
8
detection of 8 pg/mL. A method was developed for the determination of taurine in energy 
drinks with the 4-fluoro-7-nitrobenzofurazan derivatized taurine detected at 470 nm.30 A 
disodium hydrogenphosphate/citric acid buffer (pH 5.4) was used with acetonitrile and 
the derivatized analyte eluted from the column within 6 minutes. The recovery using this 
method was 98.2-99.9% and the standard deviation of the results was 0.3-0.5%.
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CHAPTER III
ANALYSIS OF NUTRITIONAL SUPPLEMENTS BY HPLC
Introduction
HPLC is a well-established method for the quantification of nutrients. One or 
more mobile phases is pumped through a column containing the stationary phase. 
Analytes in a sample injected into this system are retained according to polarity, and 
chromatograms are produced by measuring the time at which solutes are eluted from the 
column. Careful selection and manipulation of the mobile phase or mobile phases which 
are pumped through the column provides a way to customize the resolution of a given 
combination of compounds by changing the retention times. The nutritional supplements 
analyzed by HPLC in this project all contain compounds with chromophores which
absorb in the ultra-violet spectrum and can be quantified with a UV detector.
Experimental
HPLC analysis was performed using an Agilent ZORBAX Eclipse XDB-C18 4.6 
x 150 mm column (5 μm particles). The column was kept at 30ºC. Run time was 20 
minutes with a gradient between mobile phase A (0.02M phosphate buffer, pH 2.5) and 
mobile phase B (acetonitrile). Flow rate was 2.0 mL/min.
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Table 1. Mobile phase gradient: % mobile phase B vs run time.
Time % Mobile Phase B
0-7 0-25
7-18 25-35
18-20 35-50
20-22 5
All peaks of interest eluted before 8 minutes and the remaining time was devoted 
to cleaning the column. Mobile phase A was made up with Nanopure Diamond ultrapure 
water and potassium phosphate monobasic. Solutions of pantethine, L-theanine, 5-HTP 
and glycine were prepared by dissolving in the aqueous mobile phase, while melatonin 
standard was made using 50% v/v ethanol and water as a solvent. Calibration curves were 
run using serial dilution of standards. Samples of nutritional supplements were provided 
by Sanesco International. Prolent and Lentra capsules were opened and the contents 
dissolved while Somni-TR tablets were ground with a mortar and pestle prior to 
dissolving. Samples of nutritional supplements were dissolved in mobile phase at a ratio 
of 1 capsule per 100 mL and filtered with vacuum filtration. Lentra and Somni-TR 
samples were run three times each and Prolent was run four times due to more erratic 
values. Measurements were taken at 200, 210, 225 and 280 nm for each sample. 
Absorbance is defined as the peak height in order to minimize error in case of poorly 
resolved peaks or peak tailing. Results were compared with ingredients listed on the back 
of the packaging. There were several ingredients not quantified including NSB, a 
proprietary blend of enzymes intended to increase ease of absorption.
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Results
Standard curves (absorbance vs. concentration) for five analytes were measured. 
L-Theanine, pantethine and 5-HTP standard curves were created using chromatograms 
taken at 225 nm, melatonin at 280 nm, and glycine at 210 nm. Since all samples of 
nutritional supplements were dissolved in mobile phase at a ratio of 1 tablet per 100 mL 
of solvent, the projected concentration of each ingredient in solution is 1/100th of the 
listed quantity in milligrams per milliliter. 
Table 2.  Analytes, elution time, and preferred wavelength.
Analyte Wavelength Elution time Supplements
L-theanine 225nm .97 min Lentra, Prolent (75 mg)
melatonin 280nm 7.5 min Somni-TR (2 mg)
pantethine 225nm 5.7 min Somni-TR (20 mg)
5-HTP 225nm 2.6 min Prolent (50 mg)
glycine 210 nm 0.68 min Prolent (150 mg)
L-Theanine
Prolent and Lentra are both advertised to include 75 mg of L-theanine. The 
standard curve encompasses a range of 0.125-1.00 mg/mL. When Prolent samples were 
run, the results proved to erratic with regard to L-theanine, with results ranging from 101 
to 274 mg. The 274 mg value was an outlier, being almost twice the amount of the next 
highest value of 154 mg. All of these results were higher than the 75 mg indicated by the 
ingredient listing. It is unknown what could cause this degree of variation except a 
variation in the composition of the samples which were run. Lentra results appear more 
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consistent, averaging 80 mg with a standard deviation of 3 mg. The L-theanine standard 
exhibits a large peak at around 0.97 minutes accompanied by a much smaller peak at 0.87 
minutes which is most likely a system peak, although it could also indicate a possible 
impurity or decomposition. This smaller peak is also exhibited on the chromatograms of 
Prolent and Lentra. 
Figure 2. L-theanine standard (1 mg/mL) at 225 nm.
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Figure 3.  L-theanine standard curve. Absorbance = 165 * concentration+1.24,  R2 = 0.998
0 0.2 0.4 0.6 0.8 1 1.2
0
20
40
60
80
100
120
140
160
180
L-theanine
Concentration (mg/mL)
A
bs
or
ba
nc
e
Melatonin
Somni-TR is advertised to include 2 mg of melatonin per tablet. Eight melatonin 
standards were run in concentrations ranging from 0.0125 mg/mL to 1.00 mg/mL. The 
average quantity found to be in the Somni-TR tablets was found to be 1.5 mg with a 
standard deviation of 0.4 mg. 
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Figure 4. Melatonin standard (0.125 mg/mL) at 280 nm.
Figure 5. Melatonin standard curve. Absorbance = 260 * concentration + 29.3, R2 = 0.999
0 0.2 0.4 0.6 0.8 1 1.2
0
500
1000
1500
2000
2500
3000
Melatonin
Concentration (mg/mL)
A
bs
or
ba
nc
e
15
min2.5 5 7.5 10 12.5 15 17.5 20
Norm.
0
50
100
150
200
250
300
 MWD1 H, Sig=280,16 Ref=360,100 (TAYLOR\MELATONIN000500.D)
 7.
50
1
Pantethine
Somni-TR is advertised to include 20 mg of pantethine per tablet. Four standards 
were run in in concentrations ranging from 0.050 to 0.805 mg/mL. Somni-TR samples 
show an average value of 25 mg per tablet with a standard deviation of 5 mg. 
Figure 6. Pantethine standard (0.805 mg/mL) at 225 nm.
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Figure 7. Pantethine standard curve. Absorbance = 359 * concentration + 1.50, R2 = 0.999
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Glycine
Prolent is advertised to include 150 mg of glycine per tablet. Four standards were 
run in concentrations ranging from 0.25-2.00 mg/mL. While the retention time at 0.68 
seconds  runs perilously close to the retention time of the void volume, the glycine peak 
was symmetrical. The Prolent samples had an average value of 210 mg of glycine with a 
standard deviation of 27 mg. Although the high value of glycine could be a result of 
overdosing, it is also possible that the high result is due to poor separation from an 
unknown peak eluting at 0.85 minutes or interference from other substances eluting at 
close to the void volume retention time. 
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Figure 8. Glycine standard (1 mg/mL) at 210 nm.
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Figure 9. Glycine standard curve. Absorbance = 90.7 * concentration + 8.01, R2 = 0.999
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5-HTP
Prolent is advertised to include 50 mg of amino acid 5-HTP. Four standards were 
run in concentrations ranging from 0.125 to 1.00 mg/mL. Prolent samples showed an 
average concentration of 1.56 mg/mL, or 156 mg per tablet.  The 5-HTP peak of Prolent 
samples shows some distortion, indicating that either the quantity of 5-HTP exceeds the 
linearity of the method, or that there is some interfering substance eluting at the same 
time. Another anomaly was in the 5-HTP standards, which showed well separated dual 
peaks, one at 2.6 minutes which coincided with the peaks in the Prolent chromatograms, 
as well as a second large peak at 0.85 minutes which did not appear with Prolent. For this 
reason, the latter peak was used for the standard curve. Both peaks show considerable 
tailing. The presence of the second peak in the standard indicates contamination or 
decomposition of the 5-HTP reagent, and may account for the abnormally high amount of 
5-HTP appearing in Prolent.
19
Figure 10. 5-HTP standard (1 mg/mL)  at 225 nm with peaks at 0.85 and 2.6 minutes.
Figure 11. 5-HTP standard curve. A=1310C+50.4, R2 = 0.999
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Figure 12. A chromatogram of Somni-TR at 225 nm.
Figure 13. A chromatogram of Somni-TR at 280 nm.
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Figure 14. A chromatogram of Prolent at 210 nm.
Figure 15. A chromatogram of Prolent at 225 nm.
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Figure 16. A chromatogram of Lentra at 225 nm.
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CHAPTER IV
SYNTHESIS OF DIACETYLENE MONOMERS
Introduction
Chemosensors are used to detect chemical presences in the environment by 
converting a chemical interaction into a detectable signal. Humans and other animals are 
equipped with a certain number of natural chemosensors in order to detect changes within 
the body, offensive odors, or pleasant tastes. Artificial chemosensors are developed in 
order to detect specific chemicals or sometimes entire cells and viruses. Some examples 
of analytical methods used in artificial chemosensors are surface plasmon resonance and 
the quartz crystal microbalance. Both natural and artificial chemosensors consist of a 
receptor element which recognizes the analyte and a transducer which converts the 
recognition into a readable signal. One of the challenges involved in producing artificial 
receptors is tailoring the receptor to selectively respond to a specific analyte. 
Statement of Objective
One means of creating selective receptors is to make a polymer mold of the 
analyte. Such a compound is called a molecularly imprinted polymer. 
The objective of this study was to synthesize several diacetylenes which could be 
used to build polydiacetylene sensors. To this end, attempts were made using various 
methods to synthesize diacetylenes of different functional groups and chain lengths.
24
Review of Literature
The main benefit of molecularly imprinted polymers is their ability to recognize 
analytes for which there is no known receptor. The only restriction on substances which 
can be detected in this manner is that, since the analyte must be present during 
polymerization, it must be unable to either retard the polymerization or undergo 
polymerization itself. Another of the challenges of creating molecularly imprinted 
polymers is creating new polymers suitable for this purpose. The polymer must be stable 
under a variety of conditions and it must have functional groups able to interact with an 
analyte. The polymer must be able to either form a chemical bond with the analyte which 
can be broken easily enough to enable cleaning and reuse of the polymer sensor, or it 
must be able to hold the analyte in place by hydrogen bonds, Van der Waals forces, and 
pi-pi interactions. Non-covalent interactions are preferred because this makes removal of 
the template easier and because a greater variety of functional groups may be utilized.  
Diacetylenes are a group of compounds which are notable for their optical 
characteristics in the polymerized form. Polydiacetylenes (PDAs) are brilliantly colored 
due to the excitation of π electrons along the conjugated backbone. The backbone of 
these polymers is tightly packed, and can produce two different optical states, a “blue” 
form with an absorption maximum of around 640 nm, and a “red” form with peak at 
around 540 nm.  Additionally, the red form shows fluorescence with a large peak of 
around 640 nm and a small peak of around 560 nm, while the blue form shows no 
fluorescence whatsoever31. An irreversible transformation from the blue form to the red 
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can be induced with stimuli such as heating, mechanical stress32, and the binding of target 
molecules or entire cells to tailored functional groups33. This transformation is the key to 
the potential usefulness of diacetylenes as sensory materials.  
The cause of the optical transformation in polydiacetylenes are changes in the 
conformation of the polymer backbone.34 Stress undergone by the polymer causes the 
rotation around the single bonds, thus breaking up the conjugation of the ene-yne bonds 
in the backbone.35 With the shortening of the π electron delocalization length, the 
absorption maxima shifts to shorter wavelengths.
Polydiacetylene, made from 1,4-addition of the diacetylene monomers, can be 
structured as a bulk crystal, vesicles, or thin films. Most sensors use vesicles or thin 
films. For example, a polydiacetylene thin film with sialic acid residues was shown to be 
able to detect the influenza virus by binding to the viral hemagglutinin31. The inclusion of 
synthesized receptors embedded in PDA vesicles was used to selectively detect 
catecholamines in urine via fluorescence emissions.36 Amphiphilic, water-soluble 
diacetylenes can be made to form vesicles with relative ease by addition of DMSO or 
DMF to an aqueous diacetylene solution and then polymerized by irradiation.
Diacetylene properties change according to composition of functional group and 
length of methylene spacer. Polymer conjugation length can vary according whether the 
monomer side chain contains an odd or even number of carbon atoms as well as the 
length of the side chain, with a longer side chain length and odd number of methylene 
groups contributing to higher polymerization efficiency.37
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Synthesis of Diacetylene Monomers
Proton NMR spectra were used to analyze the results of all syntheses. Samples 
were prepared in d-water or d-chloroform and then run on a Jeol 500 MHz NMR 
spectrometer (JNM-ECA500). When impurities were found, products were purified using 
gravity column chromatography. As the fractions came off the column, they were 
collected and thin layer chromatography was used on each fraction in order to determine 
which contained the product. Mobile phase was eliminated by evaporating under reduced 
pressure and NMR was repeated.
1. Sonogashira coupling of 1-octynes38 
Figure 17. Palladium catalyzed coupling of alkynes
Acetonitrile (20 mL), cuprous iodide (0.114 g), triphenylphosphine (0.47 g), and 
triethylamine (30 mL) were mixed with 1-octyne in a Schlenk flask. This mix was 
degassed by freezing with liquid nitrogen, then placed under vacuum while thawing. 
After thawing was finished, the mixture was refrozen and the thawing was repeated. 
Once this was accomplished, bis(triphenylphosphine)palladium(II) dichloride was added. 
The flask was placed under a nitrogen stream and allowed to sit for 24 hours. 
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2. Pd
ACN, TEA
The solution was washed with ether into a round-bottom flask, then solvent was 
removed by evaporation. The remaining solid was dissolved in more ether, and then 
washed twice with HCl and once with tap water. The ether was dried with sodium sulfate 
and solvent was evaporated again. 
2. The addition of aldehyde functional group to diacetylene
Figure 18. Addition of aldehyde to diacetylene with butyllithium
Diacetylene from the previous step was dissolved in ether and chilled with liquid 
nitrogen under streaming nitrogen gas. N-Butyllithium (4 mL) was added dropwise over 
the course of 10 minutes in order to remove the acidic protons. Then the flask was 
allowed to warm up and a greenish brown color was observed. Solution was added to 2.5 
mL chilled dimethylformamide by cannulating. The mixed solution was left for 24 hours, 
after which a dark brown color was observed. 
Product was washed once with hydrochloric acid to remove leftover amine and 
twice with tap water to remove dimethylformamide. The remaining solvent was 
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evaporated off. Sample was purified by column chromatography using 5% ethyl acetate 
and 95% hexanes. The synthesis of this compound either did not go to completion or was 
not fully purified as NMR spectra did not match the literature.39
3.  Replacement of methyl sulfonyl with iodide group40
Figure 19. Substitution of sulfonyl with iodide
Potassium iodide (2.86 g) was dissolved in acetone, then of 1-octyne 3-sulfone 
(3.52 g) was added. This mixture was wrapped in foil and left overnight. The solvent was 
then evaporated off and the remaining solid dissolved in ether and washed with water. 
NMR showed that this reaction did not go to completion, so  the solution was redissolved 
in acetone and potassium iodide was added again, then the mixture was heated to 100 
degrees in an oil bath under reflux. Solution was dissolved in ether and washed with 
water. NMR did not match the predicted spectra.
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4. Iodination of nonyne
Figure 20. Base catalyzed iodination of terminal alkyne with sodium hydroxide
Sodium hydroxide (3 g) and iodine (2.01 g) was dissolved in methanol, then of 
nonyne (1.0 g) was added dropwise to the solution. Solution was allowed to stir for 24 
hours, and then all but 25 mL of the solvent was evaporated off. Sodium thiosulfate was 
added to the dark brown solution to remove excess iodine. The liquid was washed three 
times with ether. The ether portion was dried over sodium sulfate and then evaporated. 
The remaining solid was dissolved in hexanes to remove emulsions, then evaporated 
again. NMR did not match the predicted spectra.
5. The iodination of 3-octynol41
Figure 21. Substitution of alcohol with iodide
To start the reaction triphenylphosphine (25 g) and iodine (24 g) were dissolved in 
400 mL tetrahydrofuran. 3-Octynol (10 g) was added dropwise to this solution and left 
for 24 hours. The tetrahydrofuran was then evaporated off and the remaining solid was 
dissolved in 200 mL diethyl ether and stirred for 30 minutes. The solid, consisting of 
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triphenylphosphine and iodide salts, was filtered out with glass wool and the brown liquid 
portion was washed with sodium thiosulfate until all color was gone. Then the ether 
solution was washed with water, dried over sodium sulfate, and evaporated until dry. 
NMR did not match the predicted spectra.
6. Iodination of octyne42
Figure 22. Base catalyzed iodination of terminal alkyne with potassium hydroxide
Potassium hydroxide (6.9 g) was dissolved in 50% v/v water and methanol. Iodine 
(15.61 g) was added slowly, producing a white precipitate, followed by octyne  (13.16 g) 
dropwise over the course of ½ hour. Solution was left to sit overnight. 
The solution was washed 3 times with hexanes, which produced a filmy layer 
between the two phases. This was filtered with cotton. Leaving the hexane solution out 
overnight caused it to turn a pink color, which is removed by washing with water and 
then evaporating the solvent. The remaining product is a yellowish brown color. During 
the evaporation of solvent after TLC, the solution fell into the water bath and had to be 
re-extracted. The yield of this product was 2.644g. NMR of the unpurified product was 
similar to the literature.43
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Figure 23. NMR spectrum 1-iodo-1-octyne
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7. Coupling iodoalkyne to carboxylic acid44
Figure 24. Copper catalyzed coupling of alkyne and iodoalkyne
Pentynoic acid (1.04 g) was dissolved in aqueous potassium hydroxide. This 
solution was then mixed with a solution of cuprous chloride in isobutylamine and water, 
and hydroxylamine hydrochloride (0.017 g) was added. The 1-iodooctyne was dissolved 
in a 1:1 mixture of methanol and ether, and added dropwise to the cuprous chloride 
solution alternately with a solution of 10% hydroxylamine hydrochloride solution. The 
solution was allowed to stir for 15 minutes and then was acidified with hydrochloric acid 
to ~pH 2. The solution was then washed three times with ether, which was then washed 
with sodium thiosulfate. NMR did not match the predicted spectra.
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8. Iodination of hexadecyne42
Figure 25. Base catalyzed iodination of terminal alkyne with potassium hydroxide
Iodine (8 g) and potassium hydroxide (3.5 g) were added slowly to a mixture of 
150 mL H2O and 130 mL MeOH. Hexadecyne (16.0 g) was added dropwise over the 
course of ½ hour and left for four days, after which more iodine was added. Solution was 
left overnight for another two days. 
The solution was then washed 4 times with hexanes. The organic phase was saved 
and washed twice with sodium thiosulfate, once with sodium bicarbonate and once with 
water. The organic phase was then dried over sodium sulfate. 
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9. The coupling of 1-iodohexadecyne with 1-hexyn-6-ol44
Figure 26. Copper catalyzed coupling of iodoalkyne with terminal alkyne
A sample of  iodohexadecyne (2.1 g) from the previous reaction was dissolved in 
20 mL 50% v/v methanol and ether. Hexynol (0.6 g) was dissolved in potassium 
hydroxide solution. Cuprous chloride (0.2 g) was dissolved in 50% v/v isobutyl amine 
and water, producing a dark blue solution. The alcohol and cuprous chloride solutions 
were then mixed, and hydroxylamine hydrochloride (0.0275 g) were added, causing the 
blue cuprous chloride solution to turn green. An additional 25 mL solution of 10% 
hydroxylamine hydrochloride was made up and added to the cuprous chloride solution 
dropwise, alternating with iodide solution. The solution was allowed to sit for 20 minutes, 
then acidified to pH 3 with hydrochloric acid. This caused a yellow precipitate to form. 
Solution was washed 3 times with hexanes and the yellowish colored organic phase 
washed with sodium thiosulfate. After the solvent was evaporated, a yellow solution was 
left along with some of the yellow precipitate. This procedure was repeated a second time 
35
I
+ HO
OH
CuCl, hydroxyamine HCl
H2O, isobutylamine
with another iodohexadecyne (2.1 g). Once the procedure was worked up, the remaining 
14.5 g of reactant was reacted with 4.12 g hexynol. The product was then analyzed with 
NMR and some impurities were detected, so it was purified with column chromatography 
using a solvent of 20% ethyl acetate in hexanes, resulting in two different fractions with 
slightly different NMR spectra. Spectra were similar to predicted results although still 
containing impurities.
Figure 27. NMR spectrum of the coupled product of 1-iodohexadecyne and 1-hexyn-6-ol.
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10. Jones oxidation of diacetylene alcohol
Figure 28. Jones oxidation of alcohol using potassium dichromate
The next step was to oxidize the alcohol into a carboxylic acid. This was first 
done on the second sample of product from the column in the previous step, which was 
about 0.65 g of reactant. The product was dissolved in acetone. Potassium dichromate 
(0.84 g) and concentrated sulfuric acid (3.0 g) were dissolved in a 1:2 mixture of water 
and acetone. This solution was then added to the alcohol solution and left overnight. In 
the morning the solution was a green color with white precipitate, which was filtered out 
from the solution with glass wool. Methanol was added to dispose of the excess oxidizer. 
After 1 ½ hours, sodium bicarbonate was added to neutralize the sulfuric acid. Blue 
precipitate formed. This solid was separated out with vacuum filtration, then the solvent 
was evaporated, leaving a yellow oil. The yield from this portion of the alcohol was 
extremely low. 
The procedure was repeated on the second alcohol sample, with the exception that 
the white precipitate was saved and dissolved in chloroform.
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CHAPTER V
CONCLUSIONS
HPLC Method Development
A method was developed for the quantification of five analytes in nutritional 
supplements by reverse phase HPLC. Standard curves were created and samples of 
nutritional supplements were analyzed for ingredients, with the results compared to the 
information listed on the ingredient labels. Of the three products, Somni-TR results 
conform the most closely to the ingredient label. Somni-TR also showed the best 
separation of peaks. Measured levels of L-theanine in Lentra were also similar to the 
quantity listed on the label. Prolent was more problematic, with results for L-theanine 
appearing highly erratic and glycine and 5-HTP to be greater than that officially listed as 
ingredients. The most troubling of these results is 5-HTP, although the double-peak 
irregularity of the 5-HTP standard makes these high results questionable. There is a 
possibility that the glycine peak overlaps with some unknown substance. The purity of 
this peak could be checked by taking the ratio of absorbance at two different 
wavelengths. The ratio could then be checked against the wavelength ratio of a glycine 
standard.
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Diacetylene Synthesis
Three attempts to synthesize a diacetylene were made and seven attempts to 
functionalize a diacetylene or acetylene monomer were made. NMR results showed that 
there were problems with synthesizing and purifying the products. Although most of the 
NMR results did not match the literature values, they contribute to the total knowledge of 
synthesis of diacetylene products. 
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